Your browser doesn't support javascript.
loading
Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya.
Nyamu, David Gitonga; Guantai, Anastasia Nkatha; Osanjo, George Oyamo; Godman, Brian; Aklillu, Eleni.
Afiliação
  • Nyamu DG; Department of Pharmaceutics & Pharmacy Practice, School of Pharmacy, University of Nairobi, Nairobi, Kenya.
  • Guantai AN; Department of Pharmacology & Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya.
  • Osanjo GO; Department of Pharmacology & Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya.
  • Godman B; Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Aklillu E; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Expert Rev Cardiovasc Ther ; 18(3): 165-173, 2020 Mar.
Article em En | MEDLINE | ID: mdl-32090626
ABSTRACT

Background:

Patients' profiles affect the outcome with warfarin; however, this data, and its implications, is scarce in resource-poor countries without access to pharmacogenetics or regular INR testing.

Objectives:

To characterize the profiles of patients on long-term warfarin therapy and subsequently use these to guide future anticoagulation management.

Methods:

Cross-sectional study among 180 adult patients receiving warfarin therapy in at a leading referral hospital in Kenya. Sociodemographic characteristics were obtained through face-to-face interviews. Details of warfarin therapy, concomitant medication and comorbidities were retrieved from medical records. Associations between patients' profiles and the clinical indications of anticoagulation were computed at p ≤ 0.05.

Results:

Warfarin maintenance dose was 6.17 (±2.75) mg per day. Venous thromboembolism (56.6%) amongst obese patients (p = 0.0019) and cardioembolic events (48.3%) among males (p = 0.0316) aged ≤50 years (p = 0.0436) whose body mass indices were ≤ 25 (p < 0.0001) were the most common indications. Two-fifths and 45.0% of the patients had at least one other disease and concomitant medications.

Conclusions:

Long term warfarin therapy among Kenyans is mainly for overweight or lean middle-aged individuals suffering from venous or cardioembolic diseases. Studies should correlate patients' profiles with warfarin response to guide future management.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Varfarina / Coagulação Sanguínea / Tromboembolia Venosa Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: Expert Rev Cardiovasc Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Quênia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Varfarina / Coagulação Sanguínea / Tromboembolia Venosa Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: Expert Rev Cardiovasc Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Quênia